MRI Spectrum of Brain Involvement in Sphingosine-1-Phosphate Lyase Insufficiency Syndrome

References

1. 1.↵
   1. Choi YJ,
   2. Saba JD

   . Sphingosine phosphate lyase insufficiency syndrome (SPLIS): a novel inborn error of sphingolipid metabolism. Adv Biol Regul 2019;71:128–40 doi:10.1016/j.jbior.2018.09.004 pmid:30274713

   CrossRefPubMed
2. 2.↵
   1. Saba JD

   . Fifty years of lyase and a moment of truth: sphingosine phosphate lyase from discovery to disease. J Lipid Res 2019;60:456–63 doi:10.1194/jlr.S091181 pmid:30635364

   CrossRefPubMed
3. 3.↵
   1. Dixit D,
   2. Okuniewska M,
   3. Schwab SR

   . Secrets and lyase: control of sphingosine 1-phosphate distribution. Immunol Rev 2019;289:173–85 doi:10.1111/imr.12760 pmid:30977198

   CrossRefPubMed
4. 4.↵
   1. Kumar A,
   2. Saba JD

   . Lyase to live by: sphingosine phosphate lyase as a therapeutic target. Expert Opin Ther Targets 2009;13:1013–25 doi:10.1517/14728220903039722 pmid:19534571

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Lovric S,
   2. Goncalves S,
   3. Gee HY, et al

   . Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Invest 2017;127:912–28 doi:10.1172/JCI89626 pmid:28165339

   CrossRefPubMed
6. 6.↵
   1. Prasad R,
   2. Hadjidemetriou I,
   3. Maharaj A, et al

   . Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome. J Clin Invest 2017;127:942–53 doi:10.1172/JCI90171 pmid:28165343

   CrossRefPubMed
7. 7.↵
   1. Atkinson D,
   2. Nikodinovic Glumac J,
   3. Asselbergh B, et al

   . Sphingosine 1-phosphate lyase deficiency causes Charcot-Marie-Tooth neuropathy. Neurology 2017;88:533–42 doi:10.1212/WNL.0000000000003595 pmid:28077491

   Abstract/FREE Full Text
8. 8.↵
   1. Janecke AR,
   2. Xu R,
   3. Steichen-Gersdorf E, et al

   . Deficiency of the sphingosine-1-phosphate lyase SGPL1 is associated with congenital nephrotic syndrome and congenital adrenal calcifications. Hum Mutat 2017;38:365–72 doi:10.1002/humu.23192 pmid:28181337

   CrossRefPubMed
9. 9.↵
   1. Linhares N,
   2. Arantes R,
   3. Araujo S, et al

   . Nephrotic syndrome and adrenal insufficiency caused by a variant in SGPL1. Clin Kidney J 2018;11:462–66 doi:10.1093/ckj/sfx130 pmid:30090628

   CrossRefPubMed
10. 10.↵
    1. Bamborschke D,
    2. Pergande M,
    3. Becker K, et al

    . A novel mutation in sphingosine-1-phosphate lyase causing congenital brain malformation. Brain Dev 2018;40:480–83 doi:10.1016/j.braindev.2018.02.008 pmid:29501407

    CrossRefPubMed
11. 11.↵
    1. Settas N,
    2. Persky R,
    3. Faucz FR, et al

    . SGPL1 deficiency: a rare cause of primary adrenal insufficiency. J Clin Endocrinol Metab 2018;104:1484–90 doi:10.1210/jc.2018-02238 pmid:30517686

    CrossRefPubMed
12. 12.↵
    1. Zhao P,
    2. Liu ID,
    3. Hodgin JB, et al

    . Responsiveness of sphingosine phosphate lyase insufficiency syndrome to vitamin B6 cofactor supplementation. J Inherit Metab Dis 2020 Mar 31. [Epub ahead of print] doi:10.1002/jimd.12238 pmid:32233035

    CrossRefPubMed
13. 13.↵
    1. Milstien S,
    2. Gude D,
    3. Spiegel S

    . Sphingosine 1-phosphate in neural signalling and function. Acta Paediatr 2007;96:40–43 doi:10.1111/j.1651-2227.2007.00206.x pmid:17391440

    CrossRefPubMed
14. 14.↵
    1. Klopstock T,
    2. Tricta F,
    3. Neumayr L, et al

    . Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol 2019;18:631–42 doi:10.1016/S1474-4422(19)30142-5 pmid:31202468

    CrossRefPubMed
15. 15.↵
    1. Mitroi DN,
    2. Deutschmann AU,
    3. Raucamp M, et al

    . Sphingosine 1-phosphate lyase ablation disrupts presynaptic architecture and function via an ubiquitin-proteasome mediated mechanism. Sci Rep 2016;6:37064 doi:10.1038/srep37064 pmid:27883090

    CrossRefPubMed
16. 16.↵
    1. Mitroi DN,
    2. Karunakaran I,
    3. Graler M, et al

    . SGPL1 (sphingosine phosphate lyase 1) modulates neuronal autophagy via phosphatidylethanolamine production. Autophagy 2017;13:885–99 doi:10.1080/15548627.2017.1291471 pmid:28521611

    CrossRefPubMed
17. 17.↵
    1. Hagen N,
    2. Hans M,
    3. Hartmann D, et al

    . Sphingosine-1-phosphate links glycosphingolipid metabolism to neurodegeneration via a calpain-mediated mechanism. Cell Death Differ 2011;18:1356–65 doi:10.1038/cdd.2011.7 pmid:21331079

    CrossRefPubMed
18. 18.↵
    1. Hagen N,
    2. Van Veldhoven PP,
    3. Proia RL, et al

    . Subcellular origin of sphingosine-1-phosphate is essential for its toxic effect in lyase deficient neurons. J Biol Chem 2009;284:11346–53 doi:10.1074/jbc.M807336200 pmid:19251691

    Abstract/FREE Full Text
19. 19.↵
    1. Wang G,
    2. Bieberich E

    . Sphingolipids in neurodegeneration (with focus on ceramide and S1P). Adv Biol Regul 2018;70:51–64 doi:10.1016/j.jbior.2018.09.013 pmid:30287225

    CrossRefPubMed
20. 20.↵
    1. Mizugishi K,
    2. Yamashita T,
    3. Olivera A, et al

    . Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 2005;25:11113–21 doi:10.1128/MCB.25.24.11113-11121.2005 pmid:16314531

    Abstract/FREE Full Text